ArticleLeukemia research2022

Dermatologic adverse events associated with IDH inhibitors ivosidenib and enasidenib for the treatment of acute myeloid leukemia.

Rose Parisi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.